In the meantime, AstraZeneca is already producing doses of AZD7442, which is being developed with U.S. authorities funding that features a deal to produce the U.S. with 700,000 doses (reportedly for as much as $726 million). The corporate is in talks with different international locations, too. If the therapy passes regulatory hurdles, the hope is that it might be authorised by the tip of this yr, making it the primary long-acting Covid-19 therapy that isn’t a vaccine.
https://www.washingtonpost.com/enterprise/meet-the-non-vaccines-that-promise-to-boost-covid-immunity/2021/08/27/04d5ce2a-0701-11ec-b3c4-c462b1edcfc8_story.html?utm_source=rss&utm_medium=referral&utm_campaign=wp_business | Meet the Non-Vaccines That Promise to Enhance Covid Immunity
